MRX 951Alternative Names: MRX-951
Latest Information Update: 11 Jun 2003
At a glance
- Originator ImaRx Therapeutics
- Mechanism of Action Tubulin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Jun 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 11 Jun 2003 MRX 951 is available for licensing (http://www.imarx.com)
- 08 Jan 2001 New profile